Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective
ConclusionUse of cangrelor in patients with two or more angiographic HRFs may improve outcomes and lower hospital budgets, mainly from avoiding surgery delays necessitated by oral P2Y12 inhibitor pretreatment.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Angiography | Angioplasty | Bleeding | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Clinical Trials | Coronary Angioplasty | Economics | Heart | Percutaneous Coronary Intervention | Study